Document is current
Any future updates will be listed below
-
Authors
Piffoux, Max https://orcid.org/0000-0002-7806-101X
Leary, Alexandra
Follana, Philippe
Abdeddaim, Cyril
Joly, Florence
Bin, Sylvie
Bonjour, Maxime
Boulai, Anais
Callens, Celine
Villeneuve, Laurent https://orcid.org/0000-0002-8713-7821
Alexandre, Marine
Schwiertz, Verane
Freyer, Gilles
Rodrigues, Manuel https://orcid.org/0000-0002-5443-0802
You, Benoit https://orcid.org/0000-0002-3177-8857
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (CLIP2)
AstraZeneca (Investigator sponsored study)
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 5 February 2025
First Online: 20 February 2025
Competing interests
: Florence Joly declares links of interest with AstraZeneca for expertise and the development of UTOLA trial. Gilles Freyer declares links of interest with AstraZeneca for expertise and consulting. Manuel Rodrigues reports personal fees for serving as an advisor for AstraZeneca; travel support from AstraZeneca; funds to his institution to support research from Merck Sharp & Dohme, Janssen-Cilag, Daiichi-Sankyo. Celine Callens is a co-inventor of the ShallowHRDv2 method (International Patent Application number PCT/EP2024/061709, filed on April 28th, 2024, published on October 31st, 2024 under the International publication number WO2024/223927 and entitled « METHODS FOR DIAGNOSING A HOMOLOGOUS RECOMBINATION DEFICIENCY IN HUMAN TUMORS »). Benoit You has links of interest with Astra-Zeneca for consulting, expertise and travel expenses Philippe Follana has links of interest with Astra-Zeneca for lectures, presentations, manuscript writing or educational events. Alexandra Leary has links of interest with Astra-Zeneca for travel to congress, fees for participation to boards, and funding for trials given to its institution. The other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed. No writing assistance was used in the production of this manuscript.
